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Program beneﬁciaries. The sample contains 5000 diabetes
patients who were continuously eligible for Medicaid beneﬁt
and FAHS for at least 2 years. Medication adherence was mea-
sured with the Medication Possession Ratio (MPR) for
diabetes-speciﬁc prescriptions, statins, and ACEs/ARBs. MPR
was calculated separately for the ﬁrst 12 months (baseline) and
the following 12 months (follow-up). Costs were similarly
summed over the 12 month intervals of baseline and follow-up.
Estimation was performed with ﬁrst-difference and conditional
logistic regressions. RESULTS: Improvement in MPR between
baseline and follow-up was reﬂected in lower inpatient, emer-
gency room (ER), and total non-drug costs. A 10% improve-
ment in MPR for hypoglycemic medications reduced inpatient
costs by $127.97 (p = 0.002), ER costs by $3.72 (p = 0.003),
and total non-drug costs by $116.00 (p = 0.009) over 12
months. This reduction in inpatient costs was the result of a
shorter average length of stay: a decrease of 0.2 (p = 0.03) day
per 10% increase in MPR. Finally, a 10% improvement in
adherence with statins reduced the probability of being hospi-
talized by 4.3% (p = 0.01). CONCLUSION: This research
demonstrates the existence of signiﬁcant short-term savings
related to the improvement of medication adherence among
persons with diabetes.
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OBJECTIVE: The failure to maintain adherence to recom-
mended medication and testing regimens is associated with
excess morbidity and mortality among diabetics. This presenta-
tion focuses on the adherence patterns of diabetics enrolled in
Florida: A Healthy State (FAHS), a Medicaid disease manage-
ment program. METHODS: Attention is given to the baseline
characteristics of program participants, and the association
between them and baseline adherence to hypoglycemic agents,
ACEI, ARB, Statins, and annual tests (HbA1C, lipids, microal-
bumin, retinal exam). A matched-group comparison examined
changes in patterns of medication and test adherence at
follow-up for those enrolled in the nurse care management
module. RESULTS: A total of 8432 diabetic adults were continu-
ously enrolled for 24 months. Multivariate models evaluating
their baseline adherence to hypoglycemics, ACEI, ARB, Statins
and recommended tests were ﬁt. Those who were adherent to one
class of diabetes-related medication were 1.5 to 3.5 times more
likely to be adherent to another class of diabetes-related medi-
cation. Baseline adherence to recommended tests was associated
with 50% greater odds of adherence to hypoglycemics, ACEI and
Statin. The proﬁle of the 2597 (31%) moderate and high risk
participants that enrolled in the nurse care management module
was signiﬁcantly different than that of non-enrollees. Participants
had more comorbidities, greater service utilization and costs, and
lower medication and test adherence. In a matched-group com-
parison, nurse care management was associated with improved
odds of: ﬁlling at least one script during the study period among
those who were not using diabetes medications at baseline,
adherence to insulin among those using diabetes medications at
baseline, and adherence to recommended testing CONCLU-
SION: A pattern of overall adherence behavior was observed at
baseline. Participation in nurse care management improved
adherence to recommended diabetes medication and testing regi-
mens. It is believed that these results can be generalized to other
Medicaid populations.
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OBJECTIVE: The effect of insomnia along with the decreased
cognitive functioning associated with aging is a serious concern
within the elderly (65 years and older) population. We examined
the association of patient health care utilization and depressive
symtomatology with medication adherence in insomnia in
Medicare-HMO enrolled elderly patients. METHODS: This was
a retrospective, longitudinal cohort study which included elderly
patients (65 and older) enrolled continuously for 1–5 years in the
Medicare HMO. Medication possession ratio was used to esti-
mate the adherence in insomnia medication. Different MPR
thresholds (0.8, 0.6, 0.4 and 0.2) were used to determine non
adherence. Associations between depressive symptoms, medica-
tion adherence and health care costs were assessed using ordinary
least square multiple regressions. RESULTS: A total of 2068
patients with a primary diagnosis of insomnia were included in
the study. Sixty percent of these patients had depressive symp-
tomatology. The severity of comorbidity (Charlson index) was 4
and the patient perception of quality of life (Short Form-12
scores) were between 79 and 82. The prevalence of non adher-
ence was 70% even with a low MPR of 0.2. Insomnia patients
with depressive symptoms were 92% less likely to be adherent to
their insomnia medications (p < 0.05). After controlling other
variables, we found MPR was a good predictor of total health
care costs (10% increases in MPR for every 2% decrease in total
health care costs, p < 0.001). CONCLUSION: We found strong
associations between depressive symtomatology, medication
adherence, and health care costs in elderly patients with insom-
nia. Disease and risk management programs in managed care
settings should be used to optimize the medication adherence in
the elderly.
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OBJECTIVE: Investigate the effects of non-adherence by pro-
viders to the National Institutes of Health treatment guidelines
on the costs of care for children and adults with asthma. The
Guidelines recommend providing access to rescue medications
but restricting their overuse through controller medications.
METHODS: Pediatric (6–19 years) and adult (20–64 years)
patients with a prescription for an albuterol inhaler (AI) or an
inhaled corticosteroid (ICS) and a diagnosis for asthma between
January 1, 2001 and December 31, 2005 were identiﬁed from the
Utah Medicaid population. Patients were observed for ninety
days following the ﬁrst prescription and classiﬁed into three
groups on the basis of AI use and ICS prescription, as following:
1) less than three canisters of AI (appropriate); 2) three or more
canisters of AI (inappropriate); 3) no AI use but a prescription for
ICS (inappropriate). Once categorized as adherent (group 1) or
non-adherent (groups 2, 3), direct medical costs were estimated
for children and adults for one year using generalized linear
two-part regression models adjusting for demographics, comor-
bidities, smoking status, seasonal effects and year. RESULTS:
Of the ﬁnal sample (N = 4751), children comprised 40.4%
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(n = 1918; mean age 12.1 years; 51.2% male) and adults com-
prised 59.6% (n = 2833; mean age 39.2 years; 23.5% male).
Only 69.3% children and 58.6% adults were in the adherent
group (group 1). Compared with appropriate AI use, AI overuse
was signiﬁcantly associated with increased costs for both chil-
dren ($3541 v. $7670; mean increase 117% [p = 0.001]) and
adults ($3541 v. $5352; mean increase 21% [p = 0.009]). Simi-
larly, compared with appropriate AI use, no AI use with ICS
prescription was signiﬁcantly associated with an increase in costs
for both children and adults (mean increase 51.1% [p = 0.001]
and 37.9% [p = 0.001], respectively). CONCLUSION: Lack of
adherence with evidence-based treatment guidelines remains a
signiﬁcant problem. Interventions to improve guideline adher-
ence have the potential to reduce costs.
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OBJECTIVE: Clinical trials show the efﬁcacy of combination
beta-blocker (BB) and angiotensin converting enzyme inhibitor
(ACEI) or angiotensin II receptor blocker (ARB) therapy for
the treatment of chronic heart failure (CHF). We sought to test
the effectiveness of these drugs in day-to-day health care.
METHODS: The study was a retrospective analysis of a national
cohort of patients diagnosed with CHF from October 1, 1996
through September 30, 2002 identiﬁed from the Department of
Veterans Affairs electronic medical records system. Prevalent
cases with CHF for at least 90 days as of October 1, 2001 (index
date) were analyzed separately from incident cases identiﬁed
after index date. Patients were classiﬁed into four treatment
categories: BB, ACEI or ARB, Both and Neither according to
their exposure after index date. Multiple logistic regression
analysis was employed to assess the adjusted association between
these treatments and mortality within 1 year after index date,
controlling for demographic factors, years with CHF, 30
co-morbidities and co-medications. RESULTS: Prevalent cases:
231,109 patients were identiﬁed, with the crude death rate 8.8%.
Majority of the cohort was male (98.2%) and age >65 years
(76.1%). 28.3% of patients were on beta blockers only, 12.7%
on ACEI or ARB only, 40.1% on both and 18.9% on neither. All
three treatment options showed protective effect as compared to
Neither. Adjusted OR (95% CI) were: BB 0.646 (0.616, 0.677),
ACEI or ARB 0.708 (0.669, 0.749) and Both 0.460 (0.435,
0.488). The same pattern of protective effect remained for inci-
dent cases (N = 68,353). Adjusted OR (95% CI) were: BB 0.713
(0.652, 0.781), ACEI or ARB 0.780 (0.701, 0.868) and Both
0.614 (0.553, 0.681). CONCLUSION: Effectiveness of combi-
nation therapy of beta blockers and angiotensin inhibition was
conﬁrmed, supporting the use of evidence-based care to improve
outcomes in the “real-world” setting.
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OBJECTIVE: To estimate the lifetime cost-effectiveness of can-
desartan (Atacand) in addition to standard care in patients with
HF based on the Low-LVEF trials in the CHARM programme.
METHODS: A stochastic Markov model was developed to esti-
mate resource utilisation, morbidity and mortality effects during
and after the end of the Low-LVEF trials. Trial data were inte-
grated with external data—speciﬁc for Swedish patients—on
morbidity, mortality, and HRQoL. A Weibull hazard function
was estimated on the pooled data from the CHARM-
Alternative and the CHARM-Added trials (Low-LVEF) to
capture the treatment effect of candesartan during 40 months of
follow up. Active treatment is modeled to continue until death,
with identical mortality rates in both arms after end of follow-
up. Age speciﬁc mortality rates were supplied by the Swedish
HF registry. Medical resource were recorded in the CHARM
trials and priced according to public Swedish DRG-tariffs. TTO
based QALY weight estimates for NYHA-classes derive from a
study of 323 Swedish HF patients. Beneﬁts and costs were dis-
counted at 3%. RESULTS: The expected lifetime per patient
direct medical costs and QALYs for candesartan and placebo
were SEK371,000 and SEK 352,000 (1 USD = SEK6.40) and
5.84 and 5.43 QALYs (8.75LY vs 8.17LY) respectively. This
corresponds to an ICER per QALY gained of approximately
SEK46,000 (SEK33,000 per LYG). The CEAC shows that the
likelihood of candesartan representing the cost effective treat-
ment strategy is 0.633, 0.969 and 1 at a willingness-to-pay at
SEK50,000, 60,000, and 70,000 respectively. CONCLUSION:
Candesartan reduces cardiovascular death, hospital admissions,
and all-cause mortality in patients with HF and LVEF  40%
when added to standard therapies. The present study suggests
that long-term treatment with candesartan is highly cost-
effective, both as an alternative to and in addition to ACE-
inhibition, in HF.
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OBJECTIVE: To present immediate and long-term data on the
clinical and economic outcomes associated with major bleeding
during coronary artery bypass graft (CABG) surgery requiring
cardiopulmonary bypass (CPB). METHODS: Using data from
the United States Medicare Public Use Files, we examined clinical
and economic outcomes for patients 65 who underwent an
incident CABG requiring CPB in 2003. Patients were stratiﬁed as
to bleeding status with “Major bleeding” deﬁned as 4 units of
blood transfused. We followed patients for up to two years after
surgery, and compared discharge status, immediate and long-
term morbidity and mortality, and immediate and long-term
costs between those experiencing major bleeding and those not.
A16 Abstracts
